Your browser is no longer supported. Please, upgrade your browser.
CLSD [NASD]
Clearside Biomedical, Inc.
Index- P/E- EPS (ttm)-0.39 Insider Own7.90% Shs Outstand49.07M Perf Week-9.26%
Market Cap135.93M Forward P/E- EPS next Y-0.41 Insider Trans14.03% Shs Float44.95M Perf Month-6.84%
Income-18.20M PEG- EPS next Q-0.10 Inst Own37.70% Short Float2.13% Perf Quarter-42.35%
Sales7.90M P/S17.21 EPS this Y51.40% Inst Trans1.25% Short Ratio3.18 Perf Half Y80.15%
Book/sh0.18 P/B13.61 EPS next Y-36.70% ROA-91.60% Target Price- Perf Year25.00%
Cash/sh- P/C- EPS next 5Y- ROE-210.40% 52W Range1.25 - 4.53 Perf YTD-10.58%
Dividend- P/FCF- EPS past 5Y15.30% ROI-183.00% 52W High-44.81% Beta1.39
Dividend %- Quick Ratio1.80 Sales past 5Y- Gross Margin- 52W Low99.99% ATR0.23
Employees33 Current Ratio1.80 Sales Q/Q-99.40% Oper. Margin- RSI (14)40.32 Volatility10.19% 8.51%
OptionableYes Debt/Eq0.11 EPS Q/Q-98.70% Profit Margin- Rel Volume0.34 Prev Close2.45
ShortableYes LT Debt/Eq0.00 EarningsMay 17 AMC Payout- Avg Volume301.80K Price2.50
Recom2.20 SMA20-11.74% SMA50-10.19% SMA2005.93% Volume33,782 Change2.04%
May-13-20Initiated ROTH Capital Buy $8
Aug-09-19Downgrade Needham Buy → Hold
Nov-05-18Downgrade Stifel Buy → Hold
Nov-05-18Downgrade JP Morgan Overweight → Underweight
Nov-05-18Downgrade Cowen Outperform → Market Perform
Mar-06-18Reiterated Needham Buy $18 → $22
May-25-17Initiated JMP Securities Mkt Outperform $21
Feb-24-17Initiated JP Morgan Overweight $19
Nov-10-16Reiterated Needham Buy $16 → $24
Oct-24-16Reiterated Stifel Buy $13 → $23
May-10-21 03:00PM  
07:05AM  
May-04-21 07:05AM  
May-03-21 07:05AM  
Apr-05-21 07:05AM  
Mar-19-21 01:58AM  
Mar-10-21 05:35PM  
04:05PM  
01:30PM  
07:25AM  
Mar-03-21 12:30PM  
Mar-02-21 07:05AM  
Feb-24-21 07:05AM  
Feb-23-21 07:05AM  
Feb-16-21 07:05AM  
Feb-08-21 07:05AM  
Feb-02-21 05:31AM  
Jan-22-21 10:18AM  
Jan-18-21 12:55AM  
Jan-14-21 08:55AM  
Jan-13-21 12:00PM  
Jan-12-21 07:05AM  
Jan-06-21 07:05AM  
Nov-27-20 04:53PM  
Nov-16-20 07:05AM  
Nov-11-20 07:05AM  
Nov-10-20 04:05PM  
02:45PM  
Oct-30-20 07:05AM  
Oct-27-20 05:24AM  
Sep-23-20 07:05AM  
Sep-11-20 08:30AM  
Sep-09-20 04:05PM  
08:30AM  
Sep-02-20 08:37AM  
Aug-26-20 07:05AM  
Aug-10-20 06:45PM  
04:05PM  
04:02PM  
Aug-04-20 07:05AM  
Aug-03-20 12:31PM  
Jul-30-20 07:05AM  
Jul-29-20 12:33PM  
Jul-27-20 07:05AM  
Jun-22-20 12:00PM  
Jun-17-20 07:05AM  
Jun-04-20 06:23PM  
09:46AM  
May-08-20 08:45AM  
07:05AM  
May-06-20 12:30PM  
Apr-28-20 07:05AM  
Apr-22-20 07:05AM  
Apr-09-20 07:05AM  
Apr-08-20 07:05AM  
Mar-30-20 08:15PM  
Mar-11-20 05:45PM  
04:05PM  
04:04PM  
04:03PM  
02:30PM  
Mar-04-20 12:30PM  
Feb-27-20 07:05AM  
Feb-26-20 07:05AM  
Feb-25-20 07:05AM  
Feb-05-20 07:05AM  
Jan-28-20 07:36AM  
07:00AM  
Jan-20-20 06:28AM  
Jan-06-20 07:05AM  
Dec-31-19 07:09AM  
Dec-24-19 12:15PM  
Dec-18-19 09:10AM  
Nov-29-19 10:29AM  
Nov-22-19 05:19PM  
Nov-13-19 04:05PM  
Nov-06-19 07:05PM  
04:05PM  
Oct-30-19 04:05PM  
07:05AM  
Oct-23-19 07:54AM  
06:55AM  
Oct-17-19 04:05PM  
Oct-13-19 04:33PM  
Oct-03-19 07:05AM  
Sep-19-19 07:05AM  
Sep-17-19 06:27AM  
Sep-09-19 09:38PM  
12:58PM  
Sep-04-19 07:00AM  
Sep-03-19 04:05PM  
Aug-28-19 10:34AM  
Aug-22-19 07:05AM  
Aug-07-19 08:25PM  
04:05PM  
Aug-06-19 04:35PM  
Jul-31-19 04:30PM  
07:05AM  
Jul-18-19 07:05AM  
Jul-09-19 07:05AM  
Clearside Biomedical, Inc., a biopharmaceutical company, engages in the developing and delivering treatments that restore and preserve vision for people with serious eye diseases. Its product includes CLS-AX, an axitinib for suprachoroidal injection which is in Phase 1/2a clinical trial. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LASEZKAY GEORGE MCEOMar 19Sale2.823,3709,503430,239Mar 23 05:16 PM
Hutson Nancy JDirectorMar 12Buy3.105,00015,52510,000Mar 15 04:50 PM
LASEZKAY GEORGE MCEOMar 02Sale3.376,00020,220433,609Mar 03 07:33 PM
Thorp ClayDirectorFeb 10Sale4.4332,873145,6273,433,521Feb 12 05:22 PM
WHITMORE BRADFORD T10% OwnerJan 06Buy2.85350,750999,9883,529,845Jan 07 09:49 AM
WHITMORE BRADFORD T10% OwnerDec 24Buy1.9551,19599,8973,179,095Dec 28 10:30 AM
LASEZKAY GEORGE MCEODec 21Sale2.073,3306,893299,359Dec 23 04:28 PM
WHITMORE BRADFORD T10% OwnerDec 02Buy1.9553,900105,0513,127,900Dec 02 04:22 PM
WHITMORE BRADFORD T10% OwnerNov 24Buy1.6562,000102,0463,074,000Nov 24 04:46 PM
WHITMORE BRADFORD T10% OwnerNov 16Buy1.6962,000104,9293,012,000Nov 16 04:36 PM
LASEZKAY GEORGE MCEOSep 22Sale1.5913,41121,323302,689Sep 24 04:42 PM
Humphries William D.DirectorAug 18Buy1.785,5869,9435,586Aug 18 07:53 PM
WHITMORE BRADFORD T10% OwnerAug 13Buy1.6550,00082,5602,950,000Aug 13 04:01 PM
WHITMORE BRADFORD T10% OwnerAug 12Buy1.63300,000489,1202,900,000Aug 13 04:01 PM
Deignan Charles A.Chief Financial OfficerJun 01Sale1.8814,99228,185220,827Jun 03 04:43 PM
Hutson Nancy JDirectorMay 20Buy1.855,0009,2505,000May 21 04:50 PM